The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 12, 2001, Pages 1611-1619

  Johnson, B M ^a   Charman, W N ^a   Porter, C J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO] 2 (4 HYDROXY 3 METHOXYPHENYL) 2 ISOPROPYLVALERONITRILE; CYTOCHROME P450 3A; DEALKYLNORVERAPAMIL; DEALKYLVERAPAMIL; DRUG METABOLITE; ENZYME; GLYCOPROTEIN P; MIDAZOLAM; NORVERAPAMIL; VERAPAMIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CELL MEMBRANE TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION CHAMBER; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TRANSPORT; ENZYME METABOLISM; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MALE; MEAN RESIDENCE TIME; NONHUMAN; PROTEIN TRANSPORT; RAT; SEROSA;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCYTES; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VERAPAMIL;

EID: 0035675648     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011778214     Document Type: Article

References (32)

1. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers - The influence of culturing conditions and drug exposure on P-gp expression levels
2. Intestinal drug metabolism and antitransport processes - A potential paradigm shift in oral drug delivery
3. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans
4. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein
5. 14C]verapamil in man
6. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine
7. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
8. Gut wall metabolism of verapamil in older people - Effects of rifampicin-mediated enzyme induction
9. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells - Interaction between the two biochemical barriers to intestinal transport
10. Clinical pharmacokinetics of verapamil
11. Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines
12. Carrier-mediated transport and efflux mechanisms in Caco-2 cells
13. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4
14. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach
15. Identification of P450 enzymes involved in metabolism of verapamil in humans
16. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells
17. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system
18. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein
19. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells
20. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine
21. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats
22. Jejunal absorption and metabolism of R/S-verapamil in humans
23. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans
24. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α, 25-dihydroxy-vitamin D3
25. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
26. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
27. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
28. Active secretion and enterocytic drug metabolism barriers to drug absorption
29. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies
30. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
31. Drug metabolism
32. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds